MTF2 and sarcoma: In contrast, bladder urothelial carcinoma, cholangiocarcinoma, diffuse large B-cell lymphoma, esophageal carcinoma, GBM, head and neck squamous cell carcinoma, clear cell renal cell carcinoma, pancreatic adenocarcinoma, sarcoma, stomach adenocarcinoma, and thymoma show at least a 25% increase in MTF2 expression compared to normal tissue.